Icahn's Golden Touch Finds MedImmune (MEDI)

Carl Icahn has the golden touch.

This morning, another one of his target companies, MedImmune, Inc. (Nasdaq: MEDI), said they hired Goldman Sachs to explore strategic alternatives, sending the stock up 12%.

The company said, "indications of interest by major pharmaceutical companies, coupled with recent expressions by certain stockholders of dissatisfaction with the company's short-term stock price performance, have led the board to authorize management to gather information regarding possible strategic interest in acquiring the company."

In its latest 13F, Carl Icahn's Icahn Management noted they built up a 2.775 million shares stake (1.2%) in MEDI.